



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/724,611	12/02/2003	Eric Cossement	2003-1710	2591	
513	7590 11/22/200		EXAMINER		
	OTH, LIND & PON	BERNHARDT, EMILY B			
2033 K STR SUITE 800	033 K STREET N. W.		ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20006-1021			1624		
		·	DATE MAILED: 11/22/200	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/724,611	COSSEMENT ET AL.		
		Examiner	Art Unit		
		Emily Bernhardt	1624		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
THE MAILING DATE (- Extensions of time may be a after SIX (6) MONTHS from - If the period for reply specification of the second	OF THIS COMMUNICATION. vailable under the provisions of 37 CFR 1.13 the mailing date of this communication. ad above is less than thirty (30) days, a reply iffied above, the maximum statutory period w t or extended period for reply will, by statute, fice later than three months after the mailing	IS SET TO EXPIRE 3 MONTH(6(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE date of this communication, even if timely filed	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1) Responsive to c	communication(s) filed on 07 Se	eptember 2004.			
2a)⊠ This action is FI	NAL. 2b) This	action is non-final.			
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4a) Of the above 5) ☐ Claim(s) 6) ☑ Claim(s) <u>11</u> is/a 7) ☐ Claim(s)					
Application Papers	•				
9) The specification	n is objected to by the Examine	r. ·			
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
		ion is required if the drawing(s) is ob aminer. Note the attached Office			
Priority under 35 U.S.C.	§ 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)	·				
1) Notice of References Cite		4) Interview Summary			
	Patent Drawing Review (PTO-948) tatement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate Patent Application (PTO-152)		

Application/Control Number: 10/724,611

Art Unit: 1624

In view of applicants' response filed 9/7/04 the following still applies.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim 11 is rejected under 35 U.S.C. 102(b) as being anticipated by Cossement for reasons given in previous action.

Applicants' traverse is unpersuasive for more than one reason. First, there remains no purity limitation so the claim language reads at the very least on the prior art racemate, ceterizine, *per se*. Note In re Adamson 125 USPQ 233.

Additionally, there is a description to resolve the racemate into its stereoisomers which constitutes a description for the instant levo isomer's use as well. One reading Cossement would include **all** forms of cetirizine as having the uses disclosed on p.1 since the reference is directed to better ways of preparing cetirizine and its 2 isomers. One looks to higher yielding processes for making useful (not useless) products which is how applicants' own specification synopsizes the Cossement (commonly owned with common inventors) reference.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 10/724,611

Art Unit: 1624

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Bernhardt whose telephone number is 571-272-0664.

If attempts to reach the examiner by telephone are unsuccessful, the acting supervisor for AU 1624, James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 10/724,611

Art Unit: 1624

Emily Bernhardt Primary Examiner Art Unit 1624